• Home
• >
• News
• >
• Hikma and MedLabs Laboratories Sign an Agreement to Bring Innovative Cancer Diagnostic Technology to Jordan

Hikma and MedLabs Laboratories Sign an Agreement to Bring Innovative Cancer Diagnostic Technology to Jordan

Amman, 27 May 2024 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, recently signed an agreement with MedLabs Laboratories to introduce Guardant Health’s portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumour mutation profiling across all solid cancers. Under the agreement, MedLabs Laboratories will offer these testing kits to patients throughout the Kingdom, collecting blood samples and coordinating the processing.

Earlier this year, Hikma signed an exclusive agreement with leading precision oncology company, Guardant Health, to commercialise and market its biopsy tests in the Middle East and North Africa (MENA). These encompass Shield™ for colorectal cancer screening and early detection; Guardant Reveal™ for minimal residual disease detection and recurrence monitoring; and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling (CGP) across all solid cancers.

Commenting on the agreement, Hikma Executive Vice Chairman and President of MENA, Mazen Darwazah, said: “This agreement with MedLabs, which serves as part of a pioneering accredited medical laboratories network in the region, aligns with Hikma’s promise to put better health within reach every day by providing access to high-quality, next-generation sequencing (NGS) solutions that can potentially transform cancer care. Through this partnership, we are helping cancer patients at all stages of the disease – from cancer screening to monitoring recurrence and ultimately to guiding treatment decisions. As a leading healthcare company with a robust oncology portfolio, we at Hikma are committed to advancing precision medicine for improved treatment outcomes, bringing health and hope to cancer patients facing this challenging journey.”

In turn, MedLabs Laboratories CEO and Chairman, Dr. Hassib Sahyoun, stated: “This agreement aligns with MedLabs’ future plans where genomics plays a pivotal role. As a pioneering lab in establishing and implementing the latest technologies in the genomics department with state-of-the-art testing laboratories, we believe that DNA and genetics testing will lead the way in the future of medicine.”

– ENDS –

Enquiries

Hikma Pharmaceuticals PLC

Dana Husseini                                                                         + 962 6 5802900

Associate Director, MENA Communications                           Dalhusseini@Hikma.com

Zaina AlAtiyat                                                                          + 962 6 5802900

Manager, Communication                                                       Zalatiyat@Hikma.com

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people’s lives. We’re committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,800 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

About MedLabs

Created in Jordan in 1993, MedLabs Consultancy Group is a pioneering Jordanian Company in the field of laboratory medicine that has become the fastest and largest growing network of private medical laboratories in the Levant region.

MedLabs is accredited by the College of American Pathologists (CAP), ISO 15189, ISO 9001:2015, and HCAC. It has also received theKing Abdullah II Award for Excellence (2011). As the market leader, it operates through 74 branches in Jordan, Palestine, Iraq, Ireland, and UAE, and employs over 600 highly trained technical and non-technical personnel, including a team of medical consultants covering all subspecialties of laboratory medicine, all focusing on ensuring excellent customer experience.

MedLabs deploys leading-edge technology, with its reference laboratory offering more than 1,000 laboratory tests including genetics, metabolic disorders and anatomic surgical pathology to medical laboratories across Jordan, the Middle East, Arabian Gulf and North Africa.